Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Total Debt (2017 - 2024)

Organogenesis Holdings has reported Total Debt over the past 8 years, most recently at $62.1 million for Q3 2024.

  • Quarterly results put Total Debt at $62.1 million for Q3 2024, down 8.11% from a year ago — trailing twelve months through Sep 2024 was $62.1 million (down 8.11% YoY), and the annual figure for FY2023 was $66.2 million, down 6.41%.
  • Total Debt for Q3 2024 was $62.1 million at Organogenesis Holdings, down from $63.5 million in the prior quarter.
  • Over the last five years, Total Debt for ORGO hit a ceiling of $73.9 million in Q3 2021 and a floor of $11.7 million in Q1 2020.
  • Median Total Debt over the past 5 years was $66.2 million (2023), compared with a mean of $59.3 million.
  • Biggest five-year swings in Total Debt: tumbled 74.07% in 2020 and later surged 412.14% in 2021.
  • Organogenesis Holdings' Total Debt stood at $26.7 million in 2020, then surged by 175.35% to $73.4 million in 2021, then fell by 3.62% to $70.8 million in 2022, then dropped by 6.41% to $66.2 million in 2023, then dropped by 6.21% to $62.1 million in 2024.
  • The last three reported values for Total Debt were $62.1 million (Q3 2024), $63.5 million (Q2 2024), and $64.9 million (Q1 2024) per Business Quant data.